Biomarkers Market worth $78 1 billion in 2026 - Exclusive Report by MarketsandMarkets™ prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Point of Care Diagnostics Market worth $50.6 billion by 2025 - Exclusive Report by MarketsandMarkets
report Point of Care/Rapid Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza), Coagulation), Platform (Microfluidics, Immunoassay), Mode of Purchase (Prescription, OTC), Enduser (Hospital, e-comm, Home Care) - Global Forecast to 2025 , published by MarketsandMarkets, the global Point Of Care Diagnostics Market size is estimated to be USD 29.5 billion in 2020 and projected to reach USD 50.6 billion by 2025, at a CAGR of 11.4%.
Browse in-depth TOC on
187 - Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185
The point of care diagnostics market includes major Tier I and II suppliers like the point-of-care diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Johnson & Johnson (US), Danaher Corporation (US),
The growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent.
The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well.
Cardiac Marker Testing Market worth $5.5 billion by 2025 - Exclusive Report by MarketsandMarkets Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecasts to 2025 , published by MarketsandMarkets, the market is estimated to be USD 3.6 billion in 2020 and projected to reach USD 5.5 billion by 2025, at a CAGR of 8.9%.
Browse in-depth TOC on Cardiac Marker Testing Market
102 - Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447
The growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample coll